Guangzhou Lupeng Pharmaceutical Company LTD.
Registry sponsor category
Industry
- Other names
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Company name
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (17)
- A Food Effect Study of LP-168 Tablets in Healthy Subjects
- A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma
- A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet
- A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
- A Study of LP-118 in Patients With Advanced Tumors
- A Study of LP-128 Capsules in Healthy Subjects
- A Study of LP-168 in Healthy Volunteers
- A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
- A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
- A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
- A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
- Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
- The Mass Balance Study of LP-168 in Healthy Subjects